Trial Profile
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms POINTBREAK
- Sponsors Eli Lilly and Company
- 02 Jun 2015 Results assessing post-progression survival of PointBreak, ARIES and ECOG 4599 trials presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 04 Sep 2014 Planned End Date changed from 1 Mar 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
- 04 Jun 2013 Results comparing outcomes across different age subgroups presented at the 49th Annual Meeting of the American Society of Clinical Oncology.